Journal of Affective Disorders
April 1, 2023
Nadav Liam Modlin, Tammy M Miller, James J Rucker et al.
30 citations
Recent studies have demonstrated the promise of psilocybin therapies in creating positive changes for those with poor mental health across multiple diagnostic categories, including major depressive disorder (MDD), end-of-life anxiety, and obsessive-compulsive disorder (OCD). While there may be a large population that is eligible to participate in psilocybin therapy based on psychiatric...
Journal of Affective Disorders
April 1, 2023
Otto Simonsson, Peter S. Hendricks, Richard Chambers et al.
124 citations
Previous studies have investigated challenging, difficult, or distressing classic psychedelic experiences, but little is known about the prevalence and associations of such experiences. Using nationally representative data of the US adult population (N = 2822), this study examined the prevalence and associations of challenging, difficult, or distressing experiences using classic psychedelics,...
International Journal of Drug Policy
April 1, 2023
George Henry Robert Simpson, Caroline Chatwin, Elke van Hellemont
4 citations
This article presents an exploration of naturally occurring Class-A magic mushroom markets in the UK. It aims to challenge some of the mainstream narratives about drug markets and to identify features of this specific market, which will extend our understanding of how illegal drug markets operate and are structured more generally. The research presented comprises a three year ethnography of...
Cureus
April 1, 2023
Karina Wang, Yiqun Sun, Brenda Nava et al.
14 citations
Background Psilocybin use, along with other psychedelics, has seen an increased interest among professionals in the medical community due to its potential therapeutic benefits for psychiatric disorders, substance use disorders (SUD), and palliative care. While it is certain that more research is necessary as psychedelic-assisted therapy becomes more prevalent, it will most likely be future...
Mindfulness
April 1, 2023
Charlotta Simonsson, Richard Chambers, Peter S. Hendricks et al.
15 citations
Previous research has investigated potential synergies between classic psychedelics and meditation practice, but relatively little remains known about the relationship between classic psychedelic experiences and engagement with meditation practice.The purpose of this study was to investigate associations between classic psychedelic experiences and engagement with two popular types of...
Behavioral Sciences
March 31, 2023
Jonathan Joseph Dawood Hristova, Virtudes Pérez-Jover
39 citations
Depression is a common mental health issue that affects 280 million people in the world with a high mortality rate, as well as being a leading cause of disability. Psychopharmacological therapies with psychedelics, particularly those with psilocybin, are showing promising potential for the treatment of depression, among other conditions. Some of their benefits include a rapid and exponential...
Folia Pharmacologica Japonica
March 28, 2023
Daisuke Ibi
1 citation
Major depressive disorder presents a substantial global health burden, and at least 30-40% of patients exhibit treatment resistance to antidepressants. Ketamine, an NMDA receptor antagonist, is used as an anesthetic agent. In 2019, the U.S. Food and Drug Administration (FDA) approved esketamine (the S-enantiomer of ketamine) as a therapeutic agent for treatment-resistant depression; however,...
Psychiatric News
March 27, 2023
Terri D’arrigo
Back to table of contents Previous article Next article Annual MeetingFull AccessExperts to Discuss the Ethics of PsychedelicsTerri D'ArrigoTerri D'ArrigoPublished Online:27 Mar 2023https://doi.org/10.1176/appi.pn.2023.04.3.10AbstractA session at APA's Annual Meeting will cover the current state of psychedelics research and offer points to consider in the event of broad psychedelics...
Journal of Psychopharmacology
March 20, 2023
Jordan Sloshower, Hamideh Safi-Aghdam, Surbhi Pathania et al.
153 citations
Background: Several early phase studies have demonstrated that psilocybin-assisted therapy has rapid-acting and persisting antidepressant effects from just one or two doses. However, methodological limitations (e.g., placebo-control, blinding) limit interpretability of the existing literature. Methods: In an exploratory placebo-controlled, within-subject, fixed-order study, individuals with...
Journal of Psychoactive Drugs
March 18, 2023
Raman Sharma, Rachel Batchelor, Jacqueline Sin
25 citations
Renewed interest in psychedelic substances in the 21st century has seen the exploration of psychedelic treatments for various psychiatric disorders including substance use disorder (SUD). This review aimed to assess the effectiveness of psychedelic treatments for people with SUD and those falling below diagnostic thresholds (i.e. substance misuse). We systematically searched 11 databases, trial...
March 17, 2023
Terence H. W. Ching, Rachael Grazioplene, Christopher Pittenger et al.
6 citations
preprint
The Yale Program for Psychedelic Science (YPPS) supports a multi-disciplinary research community dedicated to investigating the effects of psychedelic substances on brain function, cognition, and behavior, including their therapeutic potential in treating neuropsychiatric conditions. In support of this mission, YPPS is testing the safety and efficacy of psilocybin, administered in conjunction...
Clinical Pharmacology & Therapeutics
March 15, 2023
Piet H. van der Graaf
1 citation
In the televised fictional drama "Nine Perfect Strangers," based on a novel with the same name,1 nine people gather for a retreat in a wellness resort which promises to heal and transform them. The guests discover that as part of the program the charismatic owner of "Tranquillum" has been feeding them smoothies spiked with psilocybin-containing mush room extract without their knowledge. After...
BMC Psychiatry
March 14, 2023
Rebecca S Ryan, Alex Copello, Andrew P Fox
12 citations
Microdosing psychedelic drugs is a growing phenomenon, but little is known about the experiences surrounding this. Research broadly suggests that people may use psychedelics in an attempt to self-medicate for mental health and wellbeing. However, the precise details, rationale and meaning of such attempts remains unclear, and would benefit from clarification, using tailored experiential...
Molecules
March 14, 2023
Timur Zanikov, Marta Gerasymchuk, Gregory Ian Robinson et al.
48 citations
Inflammation is an organism’s biological defense mechanism. Acute and chronic inflammation of the body triggers the production of pro- and anti-inflammatory pathways that can affect the content of cytokines in the brain and thus cause brain inflammation. Disorders such as depression and posttraumatic stress disorder (PTSD) are often associated with elevated inflammation. Recently, positive and...
Frontiers in Psychiatry
March 14, 2023
Jonathan Brett, Elizabeth Knock, Paul Liknaitzky et al.
16 citations
Methamphetamine use disorder is a chronic relapsing condition associated with substantial mental, physical, and social harms and increasing rates of mortality. Contingency management and psychotherapy interventions are the mainstays of treatment but are modestly effective with high relapse rates, while pharmacological treatments have shown little to no efficacy. Psilocybin-assisted...
Neuropharmacology
March 13, 2023
Andreas B. Wulff, Charles D. Nichols, Scott M. Thompson
30 citations
Psychedelic compounds have shown extraordinary potential in treating a wide range of neuropsychiatric disorders. Psilocybin, for example, has now been shown in several clinical trials to induce a rapid (within days) and persistent (3-12 months) improvement in human treatment-resistant depression and other neuropsychiatric conditions. Here we review the preclinical models and experimental...
March 10, 2023
Mika Turkia
preprint
In recent psychedelic therapy research, the concept of 'mystical experience' has been highlighted, as in several studies it has been identified as a significant predictor of improved outcome. Many studies mentioning the concept, for example, reports of randomized clinical trials, typically do not provide detailed examples of such experiences, however. In order to make the concept easily...
March 10, 2023
Mika Turkia
4 citations
preprint
In medicine, psychedelics were initially considered as a tool for clinicians to understand psychotic states. Based on the presented case data, a reversal of that concept is proposed: psychedelics could be conceptualized as a tool for people chronically anxious and depressed since early childhood to understand ordinary states of mind (e.g. calmness, hopefulness, relaxation, and joy). The case...
March 10, 2023
Mika Turkia
9 citations
preprint
While a relatively large body of research exists on many aspects of psychedelic therapy, articles describing a complete, successful treatment process are rarely found. This article therefore presents a case of a woman in her early forties with early complex trauma due to domestic violence, sexual abuse and poverty in her childhood, resulting in approximately three decades of treatment resistant...
Biomedicines
March 7, 2023
Hans O. Kalkman
16 citations
Depression is a major public health concern. Unfortunately, the present antidepressants often are insufficiently effective, whilst the discovery of more effective antidepressants has been extremely sluggish. The objective of this review was to combine the literature on depression with the pharmacology of antidepressant compounds, in order to formulate a conceivable pathophysiological process,...